זרבקסה 1 גרם0.5 גרם ישראל - עברית - Ministry of Health

זרבקסה 1 גרם0.5 גרם

merck sharp & dohme israel ltd - ceftolozane as sulfate; tazobactam as sodium - אבקה להכנת תמיסה מרוכזת לעירוי - tazobactam as sodium 0.5 g; ceftolozane as sulfate 1 g - ceftolozane and enzyme inhibitor

זרבקסה 1 גרם0.5 גרם ישראל - עברית - Ministry of Health

זרבקסה 1 גרם0.5 גרם

merck sharp & dohme (israel - 1996) company ltd, israel - ceftolozane as sulfate; tazobactam as sodium - אבקה להכנת תמיסה מרוכזת לעירוי - tazobactam as sodium 0.5 g; ceftolozane as sulfate 1 g - ceftolozane and enzyme inhibitor

טרקליר 62.5 מג ישראל - עברית - Ministry of Health

טרקליר 62.5 מג

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

טרקליר 125 מג ישראל - עברית - Ministry of Health

טרקליר 125 מג

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

פרזיסטה 400 מג ישראל - עברית - Ministry of Health

פרזיסטה 400 מג

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 400 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

פרזיסטה 600 מג ישראל - עברית - Ministry of Health

פרזיסטה 600 מג

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 600 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

נבלבין 20 מג ישראל - עברית - Ministry of Health

נבלבין 20 מג

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

טאלץ 80 מג ישראל - עברית - Ministry of Health

טאלץ 80 מג

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

נובוסבן אר.טי  1 מג בקבוקון ישראל - עברית - Ministry of Health

נובוסבן אר.טי 1 מג בקבוקון

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

נובוסבן אר.טי  2 מג בקבוקון ישראל - עברית - Ministry of Health

נובוסבן אר.טי 2 מג בקבוקון

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.